INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 43h ago
House PTR3h ago
SEC 13F3h ago
Robinhood Chain3h ago

Results

27,371 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$692K
1,345 sh
Jan 9, 2026
Page 573 of 685
← PrevNext →
Jan 13, 2026
traded Jan 9, 2026
+4d
SEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$503K
970 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
NS
Newcomb Matthew SChief Financial Officer
CHYMChime Financial, Inc.
Open-market sale · 10b5-1 plan
SELL$280K
10.0K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$438K
840 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$396K
766 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$707K
1,363 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$482K
937 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$493K
960 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$480K
913 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
ST
Stonehocker TimothyChief Technology Officer
SOUNSOUNDHOUND AI, INC.
Open-market sale · 10b5-1 plan
SELL$356K
29.7K sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$261K
487 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$259K
480 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$307K
588 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
BL
Brown Justin LPresident/Southwest Gas Corp.
SWXSouthwest Gas Holdings, Inc.
Open-market sale · 10b5-1 plan
SELL$246K
3,028 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$355K
681 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$293K
554 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$822K
1,560 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$507K
970 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

16
VA
Vollero AndrewChief Financial Officer
RDDTReddit, Inc.
Open-market sale · 10b5-1 plan
SELL$26K
100 sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

14
CJ
Congleton JonDirector, Chief Executive Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$294K
9,119 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

14
CV
Caldwell Nick V.Chief Product Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$176K
25.1K sh
Jan 13, 2026Jan 13, 2026
traded Jan 13, 2026
+0dSEC Form 4

Evidence

14
MK
McCarthy Brian K.Pres.,Global Sales & Field Ops
RBRKRubrik, Inc.
Open-market sale · 10b5-1 plan
SELL$289K
4,067 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

14
MK
McCarthy Brian K.Pres.,Global Sales & Field Ops
RBRKRubrik, Inc.
Open-market sale · 10b5-1 plan
SELL$281K
3,933 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$216K
400 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$246K
465 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$136K
256 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$217K
400 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$160K
299 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$110K
200 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$229K
440 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$207K
385 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$154K
280 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$79K
148 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$149K
280 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$177K
332 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
TR
Taub RebeccaDirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$145K
271 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

13
FA
Friedman Paul ADirector
MDGLMADRIGAL PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$88K
166 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

11
CJ
Congleton JonDirector, Chief Executive Officer
MLYSMineralys Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$236K
7,117 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence

11
BS
Baig SaqibChief Accounting Officer
PTONPELOTON INTERACTIVE, INC.
Open-market sale · 10b5-1 plan
SELL$35K
5,000 sh
Jan 9, 2026Jan 13, 2026
traded Jan 9, 2026
+4dSEC Form 4

Evidence

11
MK
McCarthy Brian K.Pres.,Global Sales & Field Ops
RBRKRubrik, Inc.
Open-market sale · 10b5-1 plan
SELL$140K
2,000 sh
Jan 12, 2026Jan 13, 2026
traded Jan 12, 2026
+1dSEC Form 4

Evidence